Geneos Wealth Management’s Halozyme HALO Stock Holding History

Geneos Wealth Management’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$955K	Sell	12,199 -200	-2%	-$13.6K	0.02%	555
2026 Q1	$801K	Sell	12,399 -100	-0.8%	-$7.05K	0.02%	561
2025 Q4	$841K	Buy	12,499 +200	+2%	+$13.5K	0.02%	546
2025 Q3	$902K	Buy	12,299 +1,927	+19%	+$128K	0.02%	513
2025 Q2	$540K	Buy	10,372 +6,369	+159%	+$362K	0.01%	686
2025 Q1	$255K	Buy	4,003 +53	+1%	+$3.08K	0.01%	826
2024 Q4	$189K	Sell	3,950 -100	-2%	-$5.13K	0.01%	862
2024 Q3	$232K	Sell	4,050 -500	-11%	-$28.7K	0.01%	737
2024 Q2	$238K	Buy	4,550 +200	+5%	+$8.77K	0.01%	661
2024 Q1	$177K	Hold	4,350	–	–	0.01%	726
2023 Q4	$161K	Hold	4,350	–	–	0.01%	721
2023 Q3	$166K	Hold	4,350	–	–	0.01%	729
2023 Q2	$157K	Hold	4,350	–	–	0.01%	742
2023 Q1	$166K	Sell	4,350 -200	-4%	-$9.38K	0.01%	697
2022 Q4	$259K	Buy	4,550 +600	+15%	+$30.7K	0.02%	573
2022 Q3	$156K	Sell	3,950 -9,950	-72%	-$440K	0.01%	670
2022 Q2	$618K	Sell	13,900 -400	-3%	-$17.3K	0.03%	442
2022 Q1	$570K	Sell	14,300 -200	-1%	-$7.12K	0.02%	497
2021 Q4	$583K	Sell	14,500 -400	-3%	-$14.9K	0.02%	526
2021 Q3	$607K	Sell	14,900 -250	-2%	-$10.5K	0.02%	521
2021 Q2	$703K	Sell	15,150 -1,060	-7%	-$46.9K	0.03%	468
2021 Q1	$809K	Buy	16,210 +10	+0.1%	+$457	0.02%	491
2020 Q4	$670K	Sell	16,200 -4,550	-22%	-$164K	0.03%	456
2020 Q3	$540K	Sell	20,750 -2,250	-10%	-$62.7K	0.03%	411
2020 Q2	$569K	Sell	23,000 -500	-2%	-$11.3K	0.03%	382
2020 Q1	$411K	Sell	23,500 -900	-4%	-$17.1K	0.03%	414
2019 Q4	$438K	Sell	24,400 -1,400	-5%	-$24.2K	0.02%	466
2019 Q3	$392K	Sell	25,800 -500	-2%	-$8.24K	0.02%	465
2019 Q2	$451K	Sell	26,300 -600	-2%	-$9.68K	0.03%	432
2019 Q1	$433K	Sell	26,900 -1,000	-4%	-$16.2K	0.03%	435
2018 Q4	$398K	Hold	27,900	–	–	0.03%	425
2018 Q3	$506K	Hold	27,900	–	–	0.03%	386
2018 Q2	$470K	Sell	27,900 -300	-1%	-$5.67K	0.04%	338
2018 Q1	$552K	Sell	28,200 -300	-1%	-$5.81K	0.05%	289
2017 Q4	$577K	Sell	28,500 -300	-1%	-$5.51K	0.05%	289
2017 Q3	$500K	Hold	28,800	–	–	0.05%	300
2017 Q2	$369K	Sell	28,800 -1,500	-5%	-$20K	0.04%	348
2017 Q1	$392K	Buy	30,300 +800	+3%	+$10.1K	0.04%	328
2016 Q4	$291K	Buy	29,500 +1,800	+6%	+$19.7K	0.04%	364
2016 Q3	$334K	Buy	27,700 +200	+0.7%	+$2.04K	0.05%	327
2016 Q2	$251K	Buy	27,500 +700	+3%	+$6.91K	0.04%	389
2016 Q1	$261K	Buy	+26,800	New	+$252K	0.04%	372

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geneos Wealth Management's HALO Position: Q2 2026 in Review

Geneos Wealth Management reduced its Halozyme (HALO) stake by 1.6% in Q2 2026, selling an estimated $13.6K and leaving 12,199 shares worth $955K. The position accounts for 0.02% of the portfolio, ranked #555.

Geneos Wealth Management first reported a position in HALO in Q1 2016 and has held it in 42 quarters since. 673 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

Geneos Wealth Management held 12,199 shares of Halozyme worth $955K as of Q2 2026.
Geneos Wealth Management sold 200 Halozyme shares in Q2 2026, an estimated $13.6K.
Halozyme made up 0.02% of Geneos Wealth Management's portfolio in Q2 2026, its #555 holding.
Geneos Wealth Management first reported a position in Halozyme in Q1 2016 and has held it in 42 quarters since.
673 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.